Redcare Pharmacy Reports Strong Q3 Growth, Reaffirms Full-Year Guidance

Redcare Pharmacy N.V. reported preliminary third-quarter sales figures showing robust growth across both prescription and non-prescription segments, prompting the company to reaffirm its full-year guidance. The European e-pharmacy recorded total sales of EUR 719 million in Q3 2025, representing a 25.2% increase compared to the same period last year, with both reporting segments achieving over 25% organic growth.

The company's performance in prescription medications proved particularly strong, with total Rx sales growing 42.3% to EUR 272 million. German prescription sales showed exceptional momentum, increasing 82.1% year-over-year to EUR 126 million in the third quarter. This growth trajectory positions Redcare to achieve at least EUR 500 million in Rx sales for the full year, according to company projections.

Non-prescription sales maintained solid growth, increasing 16.7% to EUR 448 million in Q3. The DACH segment, comprising Germany, Austria and Switzerland, generated EUR 587 million in sales, up 25.2% from the previous year. The International segment, covering Belgium, Italy, France and the Netherlands, grew 25.4% to EUR 132 million. Year-to-date total sales reached EUR 2.15 billion, representing a 27% increase compared to the same period in 2024.

Customer metrics showed positive trends, with active customers increasing by 200,000 to reach 13.7 million. The company's net promoter score improved significantly to well over 70, compared to 64 in the first half of the current year, indicating strong customer satisfaction and loyalty. CEO Olaf Heinrich emphasized that "growth remains profitable and cash generative, with a solid Q3 EBITDA, lifting our year-to-date margin already to our full-year guidance range of 2 to 2.5%."

The company's reaffirmation of all elements of its full-year guidance signals confidence in maintaining current momentum through the fourth quarter. Management confirmed financial steering remains fully stable throughout the current transition period, with continuity ensured until the appointment of a new CFO. Redcare Pharmacy will release the full interim report for the third quarter of 2025 on October 29, 2025, available through their investor relations portal at https://www.redcare-pharmacy.com.

This sustained growth pattern demonstrates Redcare's strengthening position in the European e-pharmacy market, particularly in the competitive German prescription medication sector. The company's ability to maintain accelerated growth while improving customer satisfaction metrics suggests effective scaling of operations and service quality. The performance has broader implications for the digital healthcare sector, indicating continued consumer shift toward online pharmacy services and validating the business model of integrated prescription and non-prescription offerings.